21 September 2026 (Navroze Bureau) : Alzheimer’s disease does not usually begin with a sudden loss of memory. The changes can start in the brain years before noticeable symptoms appear, gradually affecting the way brain cells communicate, function and eventually survive.
Scientists now understand Alzheimer’s as a progressive disease involving several biological changes rather than simply a normal consequence of ageing.
Early Changes Can Begin Before Symptoms
One of the earliest changes associated with Alzheimer’s is the abnormal accumulation of amyloid-beta, a protein that can form plaques between brain cells.
Another protein, tau, can become abnormally altered and form tangles inside neurons. These changes interfere with communication between nerve cells and are associated with progressive damage to brain tissue.
Amyloid and tau changes can develop before a person notices significant problems with memory or thinking.
Why Memory Is Often Affected First
The brain regions involved in forming and retrieving memories are particularly vulnerable during the early stages of Alzheimer’s.
The hippocampus, a structure important for creating new memories, is among the areas that can be affected early.
As nerve-cell communication becomes impaired, a person may begin forgetting recently learned information, repeating questions or struggling to remember conversations and appointments.
Brain Cells Gradually Lose Their Connections
Healthy neurons constantly communicate through connections called synapses.
In Alzheimer’s disease, abnormal proteins, inflammation and other biological changes can interfere with these connections. As synapses are lost, communication between brain cells becomes less efficient.
This helps explain why early Alzheimer’s can affect complex thinking even before extensive neuron loss occurs.
Inflammation Also Plays a Role
Alzheimer’s is not only a disease of abnormal protein accumulation.
The brain’s immune cells, particularly microglia, respond to damaged cells and abnormal proteins. In some circumstances, prolonged or dysregulated immune activity can contribute to inflammation and further neuronal damage.
Researchers are studying how this inflammatory response interacts with amyloid, tau and other changes in the brain.
Tau Damage Spreads Through the Brain
As Alzheimer’s progresses, abnormal tau can spread through interconnected brain regions.
This progression is associated with worsening problems involving memory, language, attention, reasoning and eventually the ability to perform everyday activities.
The pattern and speed of progression can vary considerably from person to person.
Blood Vessels and Brain Health Matter Too
Research increasingly points to the importance of blood-vessel health in Alzheimer’s disease.
Conditions such as high blood pressure, diabetes, smoking and high cholesterol can damage blood vessels and affect the brain’s ability to receive oxygen and nutrients.
Vascular damage can occur alongside Alzheimer’s-related changes and may contribute to cognitive decline.
Why Symptoms Can Take Years to Appear
The brain has considerable capacity to compensate for damage.
During the early stages, healthy neural networks may partly compensate for damaged connections. This means substantial biological changes can occur before symptoms become obvious.
Once the brain’s ability to compensate is overwhelmed, memory and cognitive problems become increasingly noticeable.
From Forgetfulness to Cognitive Decline
Early symptoms may include difficulty remembering recent events, finding familiar words, managing complicated tasks or navigating unfamiliar situations.
As the disease advances, problems can extend to judgement, communication, orientation and daily activities.
Alzheimer’s is therefore a progressive neurological disease, not simply occasional forgetfulness associated with getting older.
Research Is Changing How Alzheimer’s Is Detected
Scientists are increasingly focusing on detecting Alzheimer’s-related biological changes before major symptoms develop.
Brain imaging, cerebrospinal-fluid testing and newer blood-based biomarkers can help identify abnormal amyloid and tau activity in appropriate clinical settings.
These developments are changing Alzheimer’s research from treating symptoms alone toward earlier biological detection and intervention.